I am the Research Manager at the Centre for Neuropsychopharmacology and am involved in the management and implementation of experimental medicine and translation neuroscience research projects. My main area of interest is the development and evaluation of novel PET ligands for neuroscience, as well as better understanding the cellular underpinning of the PET signal. However, I also have interests in other neuroimaging techniques such as functional and pharmacological MR.
et al., 2021, Astrocyte reactivity with late onset cognitive impairment assessed in-vivo using 11C-BU99008 PET and its relationship with amyloid load, Molecular Psychiatry, ISSN:1359-4184
et al., 2021, Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer’s disease, British Journal of Pharmacology, Vol:178, ISSN:0007-1188, Pages:654-671
et al., 2020, Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment, Journal of Psychopharmacology, Vol:35, ISSN:0269-8811, Pages:547-555
et al., 2021, ALCOHOL HANGOVER INDUCES INCREASED NEUROINFLAMMATORY RESPONSE IN A RODENT MODEL, WILEY, Pages:202A-203A, ISSN:0145-6008
et al., 2019, Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's Disease: An in vivo [11C]BU99008 PET study, International Congress of Parkinson's Disease and Movement Disorders, WILEY, Pages:S835-S836, ISSN:0885-3185